All Stories

  1. Prednisolone with azathioprine or mycophenolate mofetil as first-line therapy in autoimmune hepatitis: insights from a randomized controlled trial

    Article • Journal of Hepatology, March 2024, Elsevier

    Prof. Dr. Bart van Hoek

  2. Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis

    Article • Journal of Hepatology, October 2023, Elsevier

    Prof. Dr. Bart van Hoek

  3. Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma

    Article • JHEP Reports, September 2023, Elsevier

    Prof. Dr. Bart van Hoek

  4. Prevalence of non-alcoholic fatty liver in the general Dutch population and in groups at increased risk

    Article • Nutrition Metabolism and Cardiovascular Diseases, August 2023, Elsevier

    Prof. Dr. Bart van Hoek

  5. Skeletal muscle mass in patients with end-stage liver disease: Not only muscle size but especially muscle quality matters in relation to physical fitness

    Article • Clinical Nutrition ESPEN, June 2023, Elsevier

    Prof. Dr. Bart van Hoek

  6. Association between skeletal muscle index prior to liver transplantation and 1‐year mortality posttransplant

    Article • Journal of Parenteral and Enteral Nutrition, May 2023, Wiley

    Prof. Dr. Bart van Hoek

  7. Novel Explanted Human Liver Model to Assess Hepatic Extraction, Biliary Excretion and Transporter Function

    Article • Clinical Pharmacology & Therapeutics, May 2023, Wiley

    Prof. Dr. Bart van Hoek

  8. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study

    Article • Journal of Clinical and Translational Hepatology, March 2023, Xia & He Publishing

    Prof. Dr. Bart van Hoek

  9. Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study

    Article • BJS Open, March 2023, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  10. Epstein–Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation

    Article • Annals of Internal Medicine, February 2023, American College of Physicians

    Prof. Dr. Bart van Hoek

  11. Fibrosis-Related Gene Profiling in Liver Biopsies of PiZZ α1-Antitrypsin Children with Different Clinical Courses

    Article • International Journal of Molecular Sciences, January 2023, MDPI AG

    Prof. Dr. Bart van Hoek

  12. Defining the Value of Extracorporeal Liver Support in Acute and Acute-on-chronic Liver Failure

    Article • Journal of Clinical and Translational Hepatology, January 2023, Xia & He Publishing

    Prof. Dr. Bart van Hoek

  13. Inflammatory conditions play a role in recurrence of PSC after liver transplantation: An international multicentre study

    Article • JHEP Reports, December 2022, Elsevier

    Prof. Dr. Bart van Hoek

  14. Tacrolimus 4‐hour monitoring in liver transplant patients is non‐inferior to trough monitoring: The randomized controlled FK04 trial

    Article • Clinical Transplantation, November 2022, Wiley

    Prof. Dr. Bart van Hoek

  15. Left atrial dysfunction is an independent predictor of mortality in patients with cirrhosis treated by transjugular intrahepatic portosystemic shunt

    Article • Hepatology Communications, August 2022, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  16. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis

    Article • Clinical Gastroenterology and Hepatology, August 2022, Elsevier

    Prof. Dr. Bart van Hoek

  17. B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis

    Article • JHEP Reports, May 2022, Elsevier

    Prof. Dr. Bart van Hoek

  18. Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review

    Article • Journal of Clinical and Translational Hepatology, March 2022, Xia & He Publishing

    Prof. Dr. Bart van Hoek

  19. A multicentre outcome analysis to define global benchmarks for donation after circulatory death liver transplantation

    Article • Journal of Hepatology, February 2022, Elsevier

    Prof. Dr. Bart van Hoek

  20. Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure

    Article • JHEP Reports, December 2021, Elsevier

    Prof. Dr. Bart van Hoek

  21. Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome

    Article • American Journal of Transplantation, November 2021, Elsevier

    Prof. Dr. Bart van Hoek

  22. The Netherlands Is on Track to Meet the World Health Organization Hepatitis C Elimination Targets by 2030

    Article • Journal of Clinical Medicine, September 2021, MDPI AG

    Prof. Dr. Bart van Hoek

  23. Erratum to: Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study

    Article • Open Forum Infectious Diseases, August 2021, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  24. Oncofetal protein CRIPTO regulates wound healing and fibrogenesis in regenerating liver and is associated with the initial stages of cardiac fibrosis

    Article • June 2021, Cold Spring Harbor Laboratory Press

    Prof. Dr. Bart van Hoek

  25. Recurrence of primary sclerosing cholangitis after liver transplantation – analysing the European Liver Transplant Registry and beyond

    Article • Transplant International, June 2021, Frontiers

    Prof. Dr. Bart van Hoek

  26. Development and validation of a prognostic score for long‐term transplant‐free survival in autoimmune hepatitis type 1

    Article • United European Gastroenterology Journal, June 2021, Wiley

    Prof. Dr. Bart van Hoek

  27. Refitting the Model for End‐Stage Liver Disease for the Eurotransplant Region

    Article • Hepatology, May 2021, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  28. Population pharmacokinetics and genetics of oral meltdose tacrolimus (Envarsus) in stable adult liver transplant recipients

    Article • British Journal of Clinical Pharmacology, May 2021, Wiley

    Prof. Dr. Bart van Hoek

  29. Hypothermic Machine Perfusion in Liver Transplantation — A Randomized Trial

    Article • New England Journal of Medicine, April 2021, New England Journal of Medicine (NEJM/MMS)

    Prof. Dr. Bart van Hoek

  30. Both muscle quantity and quality are predictors of waiting list mortality in patients with end-stage liver disease

    Article • Clinical Nutrition ESPEN, April 2021, Elsevier

    Prof. Dr. Bart van Hoek

  31. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

    Article • Hepatology International, February 2021, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  32. The role of the model for end-stage liver disease-sodium score and joint models for 90-day mortality prediction in patients with acute-on-chronic liver failure

    Article • Journal of Hepatology, February 2021, Elsevier

    Prof. Dr. Bart van Hoek

  33. Direct-Acting Antiviral Treatment for Hepatitis C Genotypes Uncommon in High-Income Countries: A Dutch Nationwide Cohort Study

    Article • Open Forum Infectious Diseases, January 2021, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  34. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands

    Article • Journal of Medical Economics, January 2021, Taylor & Francis

    Prof. Dr. Bart van Hoek

  35. Invited response to “MELD calibration”

    Article • American Journal of Transplantation, January 2021, Elsevier

    Prof. Dr. Bart van Hoek

  36. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region

    Article • American Journal of Transplantation, January 2021, Elsevier

    Prof. Dr. Bart van Hoek

  37. Donor diabetes mellitus is a risk factor for diminished outcome after liver transplantation: a nationwide retrospective cohort study

    Article • Transplant International, November 2020, Frontiers

    Prof. Dr. Bart van Hoek

  38. Early Predictors of Short‐Term Prognosis in Acute and Acute Severe Autoimmune Hepatitis

    Article • Liver Transplantation, October 2020, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  39. Evaluation of Liver Graft Donation After Euthanasia

    Article • JAMA Surgery, October 2020, American Medical Association (AMA)

    Prof. Dr. Bart van Hoek

  40. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

    Article • Annals of Surgery, September 2020, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  41. Editorial: genome‐wide association studies for developing chronic hepatitis B

    Article • Alimentary Pharmacology & Therapeutics, August 2020, Wiley

    Prof. Dr. Bart van Hoek

  42. Screening for abnormal glycosylation in a cohort of adult liver disease patients

    Article • Journal of Inherited Metabolic Disease, July 2020, Wiley

    Prof. Dr. Bart van Hoek

  43. Donor hepatectomy time influences ischemia-reperfusion injury of the biliary tree in donation after circulatory death liver transplantation

    Article • Surgery, July 2020, Elsevier

    Prof. Dr. Bart van Hoek

  44. High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation

    Article • Liver International, June 2020, Wiley

    Prof. Dr. Bart van Hoek

  45. Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months

    Article • Clinical Gastroenterology and Hepatology, June 2020, Elsevier

    Nora Sipeki, Prof. Dr. Bart van Hoek

  46. The role of complement activation in autoimmune liver disease

    Article • Autoimmunity Reviews, June 2020, Elsevier

    Prof. Dr. Bart van Hoek

  47. HCC recurrence in HCV‐infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post‐hoc analysis

    Article • Transplant International, May 2020, Frontiers

    Prof. Dr. Bart van Hoek

  48. Does mucosal inflammation drive recurrence of primary sclerosing cholangitis in liver transplantion recipients with ulcerative colitis?

    Article • Digestive and Liver Disease, May 2020, Elsevier

    Prof. Dr. Bart van Hoek

  49. Selected liver grafts from donation after circulatory death can be safely used for retransplantation – a multicenter retrospective study

    Article • Transplant International, March 2020, Frontiers

    Prof. Dr. Bart van Hoek

  50. Liver retransplantation in adult recipients: analysis of a 38‐year experience in the Netherlands

    Article • Journal of Hepato-Biliary-Pancreatic Sciences, January 2020, Wiley

    Prof. Dr. Bart van Hoek

  51. Adverse events related to low dose corticosteroids in autoimmune hepatitis

    Article • Alimentary Pharmacology & Therapeutics, October 2019, Wiley

    Prof. Dr. Bart van Hoek

  52. Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant

    Article • Clinical Genitourinary Cancer, October 2019, Elsevier

    Prof. Dr. Bart van Hoek

  53. Impact of Temporary Portocaval Shunting and Initial Arterial Reperfusion in Orthotopic Liver Transplantation

    Article • Liver Transplantation, September 2019, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  54. Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis

    Article • Clinical Gastroenterology and Hepatology, September 2019, Elsevier

    Prof. Dr. Bart van Hoek

  55. Comment on “The role of graft reperfusion sequence in the development of non-anastomotic biliary strictures following orthotopic liver transplantation: A meta-analysis”

    Article • Hepatobiliary & Pancreatic Diseases International, August 2019, Elsevier

    Prof. Dr. Bart van Hoek

  56. Local but not systemic administration of mesenchymal stromal cells ameliorates fibrogenesis in regenerating livers

    Article • Journal of Cellular and Molecular Medicine, June 2019, Wiley

    Prof. Dr. Bart van Hoek

  57. Outcome of Liver Transplant Patients With High Urgent Priority: Are We Doing the Right Thing?

    Article • Transplantation, June 2019, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  58. Prognostic Importance of Increased Right Ventricular Afterload in Orthotopic Liver Transplantation Recipients With Endstage Cirrhosis

    Article • Heart Lung and Circulation, June 2019, Elsevier

    Prof. Dr. Bart van Hoek

  59. The role of proportionate kinetic growth rate fraction in future remnant liver function over volume determined by 99mTc-Mebrofenin hepatobiliary scintigraphy including SPECT and computed tomography in the risk prediction of postoperative mortality in A...

    Article • Surgery, June 2019, Elsevier

    Prof. Dr. Bart van Hoek

  60. Predictive Capacity of Risk Models in Liver Transplantation

    Article • Transplantation Direct, May 2019, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  61. Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis

    Article • Clinical Gastroenterology and Hepatology, April 2019, Elsevier

    Prof. Dr. Bart van Hoek

  62. Study protocol for a multicenter randomized controlled trial to compare the efficacy of end-ischemic dual hypothermic oxygenated machine perfusion with static cold storage in preventing non-anastomotic biliary strictures after transplantation of liver ...

    Article • BMC Gastroenterology, March 2019, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  63. 8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

    Article • Journal of Hepatology, March 2019, Elsevier

    Prof. Dr. Bart van Hoek

  64. Systematic review with meta‐analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation

    Article • Alimentary Pharmacology & Therapeutics, February 2019, Wiley

    Prof. Dr. Bart van Hoek

  65. Optimizing the Use of Geriatric Livers for Transplantation in the Eurotransplant Region

    Article • Liver Transplantation, January 2019, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  66. Association Between Black Race and Presentation and Liver-related Outcomes of Patients With Autoimmune Hepatitis

    Article • Clinical Gastroenterology and Hepatology, November 2018, Elsevier

    Dr Neil Halliday, Prof. Dr. Bart van Hoek

  67. Mesenchymal stromal cells prevent progression of liver fibrosis in a novel zebrafish embryo model

    Article • Scientific Reports, October 2018, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  68. Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates

    Article • Clinical Transplantation, October 2018, Wiley

    Prof. Dr. Bart van Hoek

  69. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

    Article • The Lancet, October 2018, Elsevier

    Chief Director, Internal Medicine Department & Diabetes Center "George Papanikolaou" General Hospital IAKOVOS AVRAMIDIS, Prof. Dr. Bart van Hoek

  70. Utilizing Mechanistic Biomarkers in Treating Paracetamol Hepatotoxicity

    Article • Hepatology, September 2018, Wiley

    Prof. Dr. Bart van Hoek

  71. Identification and Validation of the Predictive Capacity of Risk Factors and Models in Liver Transplantation Over Time

    Article • Transplantation Direct, September 2018, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  72. The One Health stewardship of colistin as an antibiotic of last resort for human health in South Africa

    Article • The Lancet Infectious Diseases, September 2018, Elsevier

    Prof. Dr. Bart van Hoek

  73. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis

    Article • Clinical and Translational Gastroenterology, June 2018, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  74. CRIPTO it in Hepatocellular Carcinoma results in this cancer being more aggressive.

    Article • The Journal of Pathology, May 2018, Wiley

    Prof. Dr. Bart van Hoek, Marianna Kruithof-de Julio

  75. A model including sarcopenia surpasses the MELD score in predicting waiting list mortality in cirrhotic liver transplant candidates: A competing risk analysis in a national cohort

    Article • Journal of Hepatology, April 2018, Elsevier

    Prof. Dr. Bart van Hoek

  76. The center effect in liver transplantation in the Eurotransplant region: a retrospective database analysis

    Article • Transplant International, March 2018, Frontiers

    Prof. Dr. Bart van Hoek

  77. Trajectories of Anxiety and Depression After Liver Transplantation as Related to Outcomes During 2-Year Follow-Up

    Article • Psychosomatic Medicine, January 2018, Wolters Kluwer Health

    Mrs Coby J.H. Annema, Prof. Dr. Bart van Hoek

  78. DSA associated with graft loss but not to biliary strictures after liver transplantation

    Article • Clinical Transplantation, December 2017, Wiley

    Prof. Dr. Bart van Hoek

  79. Current policy for allocation of donor livers in the Netherlands advantages primary sclerosing cholangitis patients on the liver transplantation waiting list-a retrospective study

    Article • Transplant International, December 2017, Wiley

    Dr Wojciech G Polak, Prof. Dr. Bart van Hoek

  80. Copeptin in acute decompensation of liver cirrhosis: relationship with acute-on-chronic liver failure and short-term survival

    Article • Critical Care, December 2017, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  81. Urokinase is safe but does not improve outcome of DCD liver transplantation

    Article • American Journal of Transplantation, November 2017, Wiley

    Prof. Dr. Bart van Hoek

  82. Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis

    Article • Gut, August 2017, BMJ

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  83. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial

    Article • Current Controlled Trials in Cardiovascular Medicine, May 2017, Springer Science + Business Media

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  84. Safety of Anti-TNF Treatment in Liver Transplant Recipients: A Systematic Review and Meta-analysis

    Article • Journal of Crohn s and Colitis, May 2017, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  85. Trajectories of anxiety and depression in liver transplant candidates during the waiting-list period

    Article • British Journal of Health Psychology, May 2017, Wiley

    Mrs Coby J.H. Annema, Prof. Dr. Bart van Hoek

  86. Short article: Impact of genetic variation in the vasopressin 1a receptor on the development of organ failure in patients admitted for acute decompensation of liver cirrhosis

    Article • European Journal of Gastroenterology & Hepatology, May 2017, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  87. A prospective cohort study on posttraumatic stress disorder in liver transplantation recipients before and after transplantation: Prevalence, symptom occurrence, and intrusive memories

    Article • Journal of Psychosomatic Research, April 2017, Elsevier

    Mrs Coby J.H. Annema, Prof. Dr. Bart van Hoek

  88. Hemodynamic response to primary prophylactic therapy with nonselective β-blockers is related to a reduction of first variceal bleeding risk in liver cirrhosis: a meta-analysis

    Article • European Journal of Gastroenterology & Hepatology, April 2017, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  89. Expert clinical management of autoimmune hepatitis in the real world

    Article • Alimentary Pharmacology & Therapeutics, December 2016, Wiley

    Professor Albert Pares, Prof. Dr. Bart van Hoek

  90. Liver test abnormalities predict complicated disease behaviour in patients with newly diagnosed Crohn’s disease

    Article • International Journal of Colorectal Disease, November 2016, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  91. Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis

    Article • Journal of Hepatology, November 2016, Elsevier

    Prof. Dr. Bart van Hoek

  92. Limited Generalizability of Registration Trials in Hepatitis C: A Nationwide Cohort Study

    Article • PLoS ONE, September 2016, PLOS

    Prof. Dr. Bart van Hoek

  93. Longterm results of liver transplantation from donation after circulatory death

    Article • Liver Transplantation, July 2016, Wiley

    Prof. Dr. Bart van Hoek

  94. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

    Article • The Lancet Infectious Diseases, June 2016, Elsevier

    Prof. Dr. Bart van Hoek

  95. Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment

    Article • Drug Safety, April 2016, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  96. Effects of preventive versus “on-demand” nutritional support on paid labour productivity, physical exercise and performance status during PEG-interferon-containing treatment for hepatitis C

    Article • Clinics and Research in Hepatology and Gastroenterology, April 2016, Elsevier

    Prof. Dr. Bart van Hoek

  97. Flushing the liver with urokinase before transplantation does not prevent nonanastomotic biliary strictures

    Article • Liver Transplantation, March 2016, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  98. Response: Limited sampling strategies for once daily tacrolimus exposure monitoring

    Article • European Journal of Clinical Pharmacology, March 2016, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  99. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma

    Article • Transplantation, January 2016, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  100. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β‐blocker for prevention of variceal rebleeding

    Article • Hepatology, December 2015, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  101. Copeptin is an independent prognostic factor for transplant‐free survival in cirrhosis

    Article • Liver International, November 2015, Wiley

    Prof. Dr. Bart van Hoek

  102. Combined effect of donor and recipient risk on outcome after liver transplantation: Research of the Eurotransplant database

    Article • Liver Transplantation, November 2015, Wiley

    Prof. Dr. Bart van Hoek

  103. Value of Magnetic Resonance Cholangiopancreatography in Assessment of Nonanastomotic Biliary Strictures After Liver Transplantation

    Article • Transplantation Direct, November 2015, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  104. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients

    Article • European Journal of Clinical Pharmacology, October 2015, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  105. Auxiliary or orthotopic liver transplantation for acute fatty liver of pregnancy: case series and review of the literature

    Article • BJOG An International Journal of Obstetrics & Gynaecology, October 2015, Wiley

    Prof. Dr. Bart van Hoek

  106. Copeptin as an Indicator of Hemodynamic Derangement and Prognosis in Liver Cirrhosis

    Article • PLoS ONE, September 2015, PLOS

    Prof. Dr. Bart van Hoek

  107. Elderly donor liver grafts are not associated with a higher incidence of biliary complications after liver transplantation: results of a national multicenter study

    Article • Clinical Transplantation, June 2015, Wiley

    Prof. Dr. Bart van Hoek

  108. Biliary Complications After Liver Transplantation From Donation After Cardiac Death Donors

    Article • Annals of Surgery, March 2015, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  109. High peak alanine aminotransferase determines extra risk for nonanastomotic biliary strictures after liver transplantation with donation after circulatory death

    Article • Transplant International, January 2015, Wiley

    Prof. Dr. Bart van Hoek

  110. HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1

    Article • Genes & Immunity, January 2015, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  111. No Association Between BMD and Prevalent Vertebral Fractures in Liver Transplant Recipients at Time of Screening Before Transplantation

    Article • The Journal of Clinical Endocrinology & Metabolism, October 2014, Endocrine Society

    Prof. Dr. Bart van Hoek

  112. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands

    Article • Scandinavian Journal of Gastroenterology, August 2014, Taylor & Francis

    Prof. Dr. Bart van Hoek

  113. Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1

    Article • Gastroenterology, August 2014, Elsevier

    Prof. Dr. Bart van Hoek

  114. Longitudinal Changes in BMD and Fracture Risk in Orthotopic Liver Transplant Recipients Not Using Bone-Modifying Treatment

    Article • Journal of Bone and Mineral Research, July 2014, Wiley

    Prof. Dr. Bart van Hoek

  115. Gastric Variceal Hemorrhage in a Noncirrhotic Patient Treated with Balloon-Occluded Retrograde Transvenous Obliteration

    Article • CardioVascular and Interventional Radiology, July 2014, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  116. Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

    Article • New England Journal of Medicine, May 2014, New England Journal of Medicine (NEJM/MMS)

    Prof. Dr. Bart van Hoek

  117. Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation

    Article • Therapeutic Drug Monitoring, April 2014, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  118. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis

    Article • Hepatology, October 2013, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  119. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective

    Article • Journal of Clinical Virology, September 2013, Elsevier

    Prof. Dr. Bart van Hoek

  120. Recipient’s Genetic R702W NOD2 Variant Is Associated with an Increased Risk of Bacterial Infections after Orthotopic Liver Transplantation

    Article • PLoS ONE, August 2013, PLOS

    Prof. Dr. Bart van Hoek

  121. MMP-2 is a disease-modifying gene in primary sclerosing cholangitis

    Article • Liver International, June 2013, Wiley

    Prof. Dr. Bart van Hoek

  122. Cytotoxic T Lymphocyte Antigen–4 +49A/G polymorphism does not affect susceptibility to autoimmune hepatitis

    Article • Liver International, March 2013, Wiley

    Prof. Dr. Bart van Hoek

  123. Acute Cellular Rejection Is Associated With Matrix Metalloproteinase-2 Genotype Chimerism After Orthotopic Liver Transplantation

    Article • Transplantation Proceedings, March 2013, Elsevier

    Prof. Dr. Bart van Hoek

  124. The price of donation after cardiac death in liver transplantation: a prospective cost-effectiveness study

    Article • Transplant International, February 2013, Frontiers

    Prof. Dr. Bart van Hoek

  125. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission

    Article • Journal of Hepatology, January 2013, Elsevier

    Prof. Dr. Bart van Hoek

  126. Preventive versus “on-demand” nutritional support during antiviral treatment for hepatitis C: A randomized controlled trial

    Article • Journal of Hepatology, November 2012, Elsevier

    Prof. Dr. Bart van Hoek

  127. Transarterial RAdioembolization versus ChemoEmbolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial

    Article • Trials, August 2012, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  128. Liver transplantation for unresectable hepatocellular carcinoma in normal livers

    Article • Journal of Hepatology, August 2012, Elsevier

    Prof. Dr. Bart van Hoek

  129. Acute liver failure, multiorgan failure, cerebral oedema, and activation of proangiogenic and antiangiogenic factors in a case of Marburg haemorrhagic fever

    Article • The Lancet Infectious Diseases, August 2012, Elsevier

    Prof. Dr. Bart van Hoek

  130. Sequential Liver Chemistry Profiling and Abdominal Ultrasound Assessments to Predict Biliary Strictures after Liver Transplantation

    Article • The Open Transplantation Journal, March 2012, Bentham Science Publishers

    Prof. Dr. Bart van Hoek

  131. Sirolimus Conversion Regimen Versus Continued Calcineurin Inhibitors in Liver Allograft Recipients: A Randomized Trial

    Article • American Journal of Transplantation, March 2012, Elsevier

    Vivian Charles McAlister, Prof. Dr. Bart van Hoek

  132. Risk factors for infection after liver transplantation

    Article • Best Practice & Research Clinical Gastroenterology, February 2012, Elsevier

    Prof. Dr. Bart van Hoek

  133. Bacterial infections in cirrhosis: role of proton pump inhibitors and intestinal permeability

    Article • European Journal of Clinical Investigation, January 2012, Wiley

    Prof. Dr. Bart van Hoek

  134. Protein energy malnutrition predicts complications in liver cirrhosis

    Article • European Journal of Gastroenterology & Hepatology, November 2011, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  135. Mannose-binding lectin and Ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation

    Article • Journal of Hepatology, October 2011, Elsevier

    Prof. Dr. Bart van Hoek

  136. Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes: authors’ reply

    Article • Alimentary Pharmacology & Therapeutics, August 2011, Wiley

    Prof. Dr. Bart van Hoek

  137. Telaprevir for Retreatment of HCV Infection

    Article • New England Journal of Medicine, June 2011, New England Journal of Medicine (NEJM/MMS)

    Professor Daniel D Shouval, Professor Eric J Lawitz, Prof. Dr. Bart van Hoek

  138. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes

    Article • Alimentary Pharmacology & Therapeutics, June 2011, Wiley

    Prof. Dr. Bart van Hoek

  139. Use of a liver from donor after cardiac death: is it appropriate for the sick or the stable?

    Article • Current Opinion in Organ Transplantation, April 2011, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  140. Clinical value of myocardial perfusion scintigraphy as a screening tool in liver transplant candidates

    Article • Liver Transplantation, March 2011, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  141. Matrix metalloproteinase 2 genotype is associated with nonanastomotic biliary strictures after orthotopic liver transplantation

    Article • Liver International, February 2011, Wiley

    Prof. Dr. Bart van Hoek

  142. Chewing khat and chronic liver disease

    Article • Liver International, January 2011, Wiley

    Prof. Dr. Bart van Hoek

  143. Two Patients with Extremely Elevated Tumor Markers: Where Is the Malignancy?

    Article • Gastroenterology Research and Practice, January 2011, Hindawi Publishing Corporation

    Prof. Dr. Bart van Hoek

  144. Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases

    Article • Liver International, December 2010, Wiley

    Prof. Dr. Bart van Hoek

  145. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008

    Article • BMC Gastroenterology, December 2010, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  146. Authors' reply: Similar liver transplantation survival with selected cardiac death donors and brain death donors (Br J Surg 2010; 97; 744–753)

    Article • British Journal of Surgery, July 2010, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  147. No beneficial effects of amantadine in treatment of chronic hepatitis C patients

    Article • Digestive and Liver Disease, July 2010, Elsevier

    Prof. Dr. Bart van Hoek

  148. Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation

    Article • Hepatology, June 2010, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  149. A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

    Article • BMC Cancer, May 2010, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  150. Similar liver transplantation survival with selected cardiac death donors and brain death donors

    Article • British Journal of Surgery, April 2010, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  151. Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Occlusion and Cavernous Transformation

    Article • Journal of Clinical Gastroenterology, November 2009, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  152. Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group

    Article • Transplantation, September 2009, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  153. Antineutrophil Cytoplasmic Antibodies in Small-Duct Primary Sclerosing Cholangitis

    Article • Gastroenterology, January 2009, Elsevier

    Prof. Dr. Bart van Hoek

  154. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis

    Article • The Lancet Oncology, January 2009, Elsevier

    Prof. Dr. Bart van Hoek

  155. Flexible Limited Sampling Model for Monitoring Tacrolimus in Stable Patients Having Undergone Liver Transplantation With Samples 4 to 6 Hours After Dosing Is Superior to Trough Concentration

    Article • Therapeutic Drug Monitoring, August 2008, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  156. Reuse of Auxiliary Liver Grafts in Second Recipients With Chronic Liver Disease

    Article • American Journal of Transplantation, November 2007, Elsevier

    Prof. Dr. Bart van Hoek

  157. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice

    Article • Alimentary Pharmacology & Therapeutics, September 2007, Wiley

    Prof. Dr. Bart van Hoek

  158. ?-Glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-?-2b in chronic hepatitis C non-responders

    Article • Liver International, August 2007, Wiley

    Prof. Dr. Bart van Hoek

  159. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis

    Article • Thrombosis and Haemostasis, January 2007, Thieme Publishing Group

    Prof. Dr. Bart van Hoek

  160. Liver Chimerism After Allogeneic Blood Stem Cell Transplantation

    Article • Transplantation Proceedings, January 2007, Elsevier

    Prof. Dr. Bart van Hoek

  161. A Novel Technique for Auxiliary Partial Liver Transplantation With Reno-Portal Anastomosis and Avoidance of the Hepatoduodenal Ligament

    Article • American Journal of Transplantation, November 2006, Elsevier

    Prof. Dr. Bart van Hoek

  162. Reply to Rijnders

    Article • Clinical Infectious Diseases, April 2006, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  163. Successful Treatment of Legionella maceachernii Pneumonia after Diagnosis by Polymerase Chain Reaction and Culture

    Article • Clinical Infectious Diseases, April 2006, Oxford University Press (OUP)

    Prof. Dr. Bart van Hoek

  164. Mannose-Binding Lectin and Liver Transplantation

    Article • Gastroenterology, November 2005, Elsevier

    Prof. Dr. Bart van Hoek

  165. Mannose Binding Lectin Gene Polymorphisms Confer a Major Risk for Severe Infections After Liver Transplantation

    Article • Gastroenterology, August 2005, Elsevier

    Prof. Dr. Bart van Hoek

  166. Preanalytical Conditions and Circulating Matrix Metalloproteinases

    Article • Transplantation, March 2005, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  167. Easy‐to‐use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation

    Article • Alimentary Pharmacology & Therapeutics, March 2005, Wiley

    Prof. Dr. Bart van Hoek

  168. Military Explosives and Health: Organic Energetic Compound Syndrome?

    Article • Medicine Conflict & Survival, October 2004, Taylor & Francis

    Prof. Dr. Bart van Hoek

  169. ASSESSMENT OF SERUM MATRIX METALLOPROTEINASES MMP-2 AND MMP-9 AFTER HUMAN LIVER TRANSPLANTATION: INCREASED SERUM MMP-9 LEVEL IN ACUTE REJECTION

    Article • Transplantation, June 2004, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  170. Switching monitoring of emulsified cyclosporine from trough level to 2-hour level in stable liver transplant patients

    Article • Liver Transplantation, January 2004, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  171. Plasma MMP–2 and MMP–9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation

    Article • Thrombosis and Haemostasis, January 2004, Thieme Publishing Group

    Prof. Dr. Bart van Hoek

  172. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome

    Article • Hepatology, January 2004, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  173. Non-alcoholic fatty liver disease: a brief review

    Article • Scandinavian Journal of Gastroenterology, January 2004, Taylor & Francis

    Prof. Dr. Bart van Hoek

  174. Serum matrix metalloproteinase MMP-2 and MMP-9 in the late phase of ischemia and reperfusion injury in human orthotopic liver transplantation

    Article • Transplantation Proceedings, December 2003, Elsevier

    Prof. Dr. Bart van Hoek

  175. Retreatment of hepatitis C non-responsive to Interferon. A placebo controlled randomized trial of Ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]

    Article • BMC Gastroenterology, August 2003, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  176. Extensive chimerism in liver transplants: Vascular endothelium, bile duct epithelium, and hepatocytes

    Article • Liver Transplantation, June 2003, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  177. Assessment of the clinical significance of serum matrix metalloproteinases MMP-2 and MMP-9 in patients with various chronic liver diseases and hepatocellular carcinoma

    Article • Thrombosis and Haemostasis, January 2003, Thieme Publishing Group

    Prof. Dr. Bart van Hoek

  178. Extrahepatic portal vein thrombosis: aetiology and determinants of survival

    Article • Gut, November 2001, BMJ

    Prof. Dr. Bart van Hoek

  179. The prognostic value of histology in the assessment of patients with Budd–Chiari syndrome

    Article • Journal of Hepatology, September 2001, Elsevier

    Prof. Dr. Bart van Hoek

  180. Monitoring response during a randomised controlled trial of escalating interferon dose for chronic hepatitis C infection: predictive value of quantitative and qualitative HCV RNA assays

    Article • Journal of Clinical Virology, August 2001, Elsevier

    Prof. Dr. Bart van Hoek

  181. SUCCESSFUL OUTCOME WITH A ???QUINTUPLE APPROACH??? OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER

    Article • Transplantation, January 2001, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  182. Hepatocellular carcinoma in glycogen storage disease type IV

    Article • Archives of Disease in Childhood, June 2000, BMJ

    Prof. Dr. Bart van Hoek

  183. Hemolytic anemia, ARDS and acute liver failure as acute presentation of Wilson disease, cured by liver transplantation

    Article • European Journal of Gastroenterology & Hepatology, December 1999, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  184. Liver Rupture after Transcatheter Arterial Chemoembolization of a Giant Hepatocellular Carcinoma

    Article • Journal of Vascular and Interventional Radiology, July 1999, Elsevier

    Prof. Dr. Bart van Hoek

  185. Auxiliary versus orthotopic liver transplantation for acute liver failure

    Article • Journal of Hepatology, April 1999, Elsevier

    Prof. Dr. Bart van Hoek

  186. Article • Digestive Diseases and Sciences, January 1999, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  187. Factor V Leiden mutation, prothrombin gene mutation and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis

    Article • European Journal of Gastroenterology & Hepatology, December 1998, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  188. Famcyclovir followed with interferon for chronic active hepatitis B resistant to interferon alone

    Article • European Journal of Gastroenterology & Hepatology, December 1998, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  189. Gravesʼ hyperthyroidism in a patient with primary sclerosing cholangitis. Coincidence or combined pathogenesis?

    Article • European Journal of Gastroenterology & Hepatology, March 1998, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  190. Campylobacter jejuni peritonitis in a patient with liver cirrhosis

    Article • European Journal of Gastroenterology & Hepatology, December 1996, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  191. The spectrum of liver disease in systemic lupus erythematosus

    Article • The Netherlands Journal of Medicine, June 1996, Elsevier

    Prof. Dr. Bart van Hoek

  192. Auxiliary liver transplantation: Regeneration of the native liver and outcome in 30 patients with fulminant hepatic failure-a multicenter European study

    Article • Hepatology, May 1996, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  193. LONG-TERM TREATMENT OF RECURRENT PERIHILAR NONANASTOMATIC BILIARY STRICTURES AFTER LIVER TRANSPLANTATION WITH EXPANDABLE METALLIC STENTS

    Article • Transplantation, August 1995, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  194. Temporary heterotopic auxiliary liver transplantation for fulminant hepatitis B

    Article • Journal of Hepatology, August 1995, Elsevier

    Prof. Dr. Bart van Hoek

  195. Inadvertent arteriovenous stenting during transjugular intrahepatic portosystemic shunt procedure and the importance of hepatic artery perfusion

    Article • CardioVascular and Interventional Radiology, May 1995, Springer Science + Business Media

    Prof. Dr. Bart van Hoek

  196. Energy expenditure and substrate metabolism in patients with cirrhosis of the liver: effects of the pattern of food intake.

    Article • Gut, January 1995, BMJ

    Prof. Dr. Bart van Hoek

  197. The Role of Portosystemic Shunts for Variceal Bleeding in the Liver Transplantation Era

    Article • Archives of Surgery, July 1994, American Medical Association (AMA)

    Prof. Dr. Bart van Hoek

  198. Syphilis in pregnant patients and their offspring

    Article • International Journal of Gynecology & Obstetrics, February 1994, Wiley

    Prof. Dr. Bart van Hoek

  199. Habitual pattern of food intake in patients with liver disease

    Article • Clinical Nutrition, October 1993, Elsevier

    Prof. Dr. Bart van Hoek

  200. Hepatic Allograft Rejection: New Developments in Terminology, Diagnosis, Prevention, and Treatment

    Article • Mayo Clinic Proceedings, January 1993, Elsevier

    Prof. Dr. Bart van Hoek

  201. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis

    Article • Hepatology, February 1992, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  202. Severe Ductopenic Rejection Following Liver Transplantation: Incidence, Time of Onset, Risk Factors, Treatment, and Outcome

    Article • Seminars in Liver Disease, February 1992, Thieme Publishing Group

    Prof. Dr. Bart van Hoek

  203. Current concepts in cell-mediated hepatic allograft rejection leading to ductopenia and liver failure

    Article • Hepatology, October 1991, Wolters Kluwer Health

    Prof. Dr. Bart van Hoek

  204. The immunology of hepatic allograft rejection

    Article • Clinical Immunology Newsletter, May 1990, Elsevier

    Prof. Dr. Bart van Hoek

  205. Indomethacin treatment in a patient with lithium-induced polyuria

    Article • Intensive Care Medicine, March 1985, Springer Science + Business Media

    Prof. Dr. Bart van Hoek